首页> 美国卫生研究院文献>Journal of Clinical Medicine >Iris-Claw Intraocular Lens Implantation in Various Clinical Indications: A 4-Year Study
【2h】

Iris-Claw Intraocular Lens Implantation in Various Clinical Indications: A 4-Year Study

机译:IRIS-爪眼内晶状体植入各种临床适应症:4年的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An iris-claw intraocular lens (IOL) has been widely used as a secondary implant in aphakic patients. The study presents the results of implanting the anterior chamber iris-claw Artisan IOL in cases of where an appropriate posterior capsular support is lacking. The study included 132 patients subjected to primary IOL implantation during complicated cataract surgery with damage to the posterior capsule (I), secondary implantation in aphakia (II), secondary implantation during penetrating keratoplasty (III), and secondary implantation during pars plana vitrectomy with luxated IOL extraction (IV). We analyzed the records of best-corrected visual acuity (BCVA), spherical equivalent (SE), intraocular pressure (IOP), and corneal endothelial cell count (cECC), taken before and 1, 2, 3, and 4 years after the surgery. BCVA depended on the time after IOL implantation and the primary indication. Four years post-surgery, the SE values were the lowest in group III. IOP was the same in all groups both before and after the surgery, but 4 years after the surgery IOP values in group IV were higher than in group III. The cECC decreased every year after the surgery in all groups, but four years after the IOL implantation, the lowest cECC values were observed in group IV. At the same time, all groups of patients showed improved BCVA, stable refraction, and a low percentage of postoperative complications.
机译:IRIS-爪眼内透镜(IOL)已被广泛用作奥波基患者中的二级植入物。该研究提出了在缺乏适当的后囊载体的情况下植入前房IRIS-爪工匠IOL的结果。该研究包括132名患者在复杂的白内障手术期间经过初级IOL植入的患者,损伤后胶囊(I),牙龈(II)中的二次植入,渗透角膜术期间(III)中的二次植入,以及在Lugaped的Pars Plana Vitectomy期间的二次植入IOL提取(IV)。我们分析了在手术前之前和1,2,3和4年之前的最佳矫正视力(BCVA),球形等同(SE),球形压(IOP)和角膜内皮细胞计数(CECC)的记录。 BCVA取决于IOL植入后的时间和主要指示。手术后四年,SE值是III组中最低的。在手术前后的所有群体中的IOP是相同的,但在IV组手术IOP值均高于III组中的4年。在所有群体手术后,CECC每年减少,但IOL植入四年后,在IV组中观察到最低的CECC值。与此同时,所有患者组都显示出改善的BCVA,稳定折射,术后并发症的低百分比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号